Some aspects of the pathogenesis of placenta accreta spectrum (PAS): pathohistology, molecular mechanisms and biomarkers (literature review)
DOI:
https://doi.org/10.15574/HW.2025.1(176).8398Keywords:
pregnancy, placenta accreta spectrum, histopathology, screening, biomarkersAbstract
Aim - to study the current state of the pathogenesis of abnormal placental invasion, existing scientific research and potential future ways of predicting and screening for abnormal placental invasion in pregnant women.
To identify relevant information on placenta accreta spectrum (PAS) for the review, a database of modern scientific literature (2014–2024) was analyzed namely, from such scientific-metric databases as Scopus, PubMed, Google Scholar and the Web of Science databases. This review is to analyze the current literature on the molecular mechanisms and pathological signaling pathways associated with PAS. We assessed the state of the available data on the role of some proteins, chemokines and other biomarkers of trophoblastic invasion. In addition, we reviewed the data on the participation of epigenetic modifications and genes in key regulatory processes of trophoblastic invasion, including apoptosis, cell proliferation, invasion and inflammation.
Conclusion: Investigation of signaling pathways involved in the pathogenesis of PAS may provide valuable tools for the development of targeted therapies. Therapeutic strategies targeting these pathways may potentially inhibit abnormal placental invasion and angiogenesis.
The authors declare no conflict of interest.
References
Abdel-Hamid AAM, Mesbah Y, Soliman MFM, Firgany AEL. (2024). Dominance of Pro-Inflammatory Cytokines Over Anti-Inflammatory Ones in Placental Bed of Creta Cases. J. Microsc. Ultrastruct. 12: 14-20. https://doi.org/10.4103/jmau.jmau_76_21; PMid:38633568 PMCid:PMC11019593
Arakaza A, Liu X, Zhu J, Zou L. (2024). Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders. J. Matern.-Fetal Neonatal Med. 37: 2305264. https://doi.org/10.1080/14767058.2024.2305264; PMid:38247274
Bailit JL, Grobman WA, Rice MM et al. (2015). Morbidly adherent placenta treatments and outcomes. Obstetrics & Gynecology. 125(3): 683-689. https://doi.org/10.1097/AOG.0000000000000680; PMid:25730233 PMCid:PMC4347990
Barrett SL, Bower C, Hadlow NC. (2008). Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenatal Diagnosis. 28(1): 28-35. https://doi.org/10.1002/pd.1898; PMid:18186146
Bartels HC, Downey P, Brennan DJ. (2024, Jul). Looking back to look forward: Has the time arrived for active management of obstetricians in placenta accreta spectrum? International Journal of Gynecology & Obstetrics. 168(1): 48-56. https://doi.org/10.1002/ijgo.15826; PMid:39045676 PMCid:PMC11649868
Bartels HC, Postle JD, Downey P, Brennan DJ. (2018). Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers. Dis. Markers. 2018: 1507674. https://doi.org/10.1155/2018/1507674; PMid:30057649 PMCid:PMC6051104
Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. (2019). Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn. Ther. 46: 187-192. https://doi.org/10.1159/000492829; PMid:30726846
Betrán AP, Ye J, Moller AB, Zhang J, Gulmezoglu AM, Torloni MR. (2016). The Increasing Trend in Caesarean Section Rates: Global, Regional and National Estimates: 1990-2014. PLoS ONE. 11: e0148343. https://doi.org/10.1371/journal.pone.0148343; PMid:26849801 PMCid:PMC4743929
Bowman ZS, Eller AG, Bardsley TR, Greene T, Varner MW, Silver RM. (2014). Risk factors for placenta accreta: A large prospective cohort. Am. J. Perinatol. 31: 799-804. https://doi.org/10.1055/s-0033-1361833; PMid:24338130
Büke B, Akkaya H, Demir S, Sağol S, Şimşek D et al. (2018, Jan). Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J Matern Fetal Neonatal Med. 31(1): 59-62. Epub 2017 Jan 17. https://doi.org/10.1080/14767058.2016.1275546; PMid:28027672
Cahill AG, Beigi R, Heine P, Silver RM, Wax JR. (2018). Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet.Gynecol. 132: e259-e275. https://doi.org/10.1097/AOG.0000000000002983
Cal G, D'Antonio F, Forlani F, Timor-Tritsch IE, Palacios-Jaraquemada JM. (2017). Ultrasound Detection of Bladder-Uterovaginal Anastomoses in Morbidly Adherent Placenta. Fetal Diagn. Ther. 41: 239-240. https://doi.org/10.1159/000445055; PMid:27160715
Cao C, Li J, Li J, Liu L, Cheng X, Jia R. (2017). Long Non-Coding RNA Uc.187 Is Upregulated in Preeclampsia and Modulates Proliferation, Apoptosis, and Invasion of HTR-8/SVneo Trophoblast Cells. J. Cell. Biochem. 118: 1462-1470. https://doi.org/10.1002/jcb.25805; PMid:27883216
Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. (2003). Unexplained elevated maternal serum α-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. American Journal of Obstetrics & Gynecology. 189(3): 775-781. https://doi.org/10.1067/S0002-9378(03)00769-5; PMid:14526312
Cheng SB, Nakashima A, Huber WJ, Davis S, Banerjee S, Huang Z et al. (2019). Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors. Cell Death Dis. 10: 927. https://doi.org/10.1038/s41419-019-2162-4; PMid:31804457 PMCid:PMC6895177
Chen P-S, Su J-L, Hung M-C. (2012). Dysregulation of MicroRNAs in cancer. J. Biomed. Sci. 19: 90. https://doi.org/10.1186/1423-0127-19-90; PMid:23075324 PMCid:PMC3482395
Chen Y, Zhang H, Han F et al. (2018). The depletion of MARVELD1 leads to murine placenta accreta via integrin β4-dependent trophoblast cell invasion. Journal of Cellular Physiology. 233: 2257-2269. https://doi.org/10.1002/jcp.26098; PMid:28708243
Cole LA. (2010). Biological functions of hCG and hCG-related molecules," Reproductive Biology and Endocrinology. 8(1): 102. https://doi.org/10.1186/1477-7827-8-102; PMid:20735820 PMCid:PMC2936313
Conover CA. (2012). Key questions and answers about pregnancyassociated plasma protein-A. Trends in Endocrinology and Metabolism. 23(5): 242-249. https://doi.org/10.1016/j.tem.2012.02.008; PMid:22463950 PMCid:PMC3348390
Costa SL, Proctor L, Dodd JM et al. (2008). Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta. 29(12): 1034-1040. https://doi.org/10.1016/j.placenta.2008.09.004; PMid:18930542
Desai N, Krantz D, Roman A, Fleischer A, Boulis S, Rochelson B. (2014). Elevated first trimester PAPP-A is associated with increased risk of placenta accreta. Prenatal Diagnosis. 34(2): 159-162. https://doi.org/10.1002/pd.4277; PMid:24226752
Dreux S, Salomon LJ, Muller F et al. (2012). Second-trimester maternal serum markers and placenta accreta. Prenatal Diagnosis. 32(10): 1010-1012. https://doi.org/10.1002/pd.3932; PMid:22729439
Duan L, Schimmelmann M, Wu Y, Reisch B, Faas M, Kimmig R et al. (2020). CCN3 Signaling Is Differently Regulated in Placental Diseases Preeclampsia and Abnormally Invasive Placenta. Front. Endocrinol. 11: 597549. https://doi.org/10.3389/fendo.2020.597549; PMid:33304321 PMCid:PMC7701218
Dugoff L. (2010). First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric out-comes. Obstetrics and Gynecology. 115(5): 1052-1061. https://doi.org/10.1097/AOG.0b013e3181da93da; PMid:20410782
Dugoff L, Hobbins JC, Malone FD et al. (2004). First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a populationbased screening study (The FASTER Trial). American Journal of Obstetrics & Gynecology. 191(4): 1446-1451. https://doi.org/10.1016/j.ajog.2004.06.052; PMid:15507981
Duzyj CM, Buhimschi IA, Motawea H et al. (2015). The invasive phenotype of placenta accreta extravillous trophoblasts associate with loss of E-cadherin. Placenta. 36(6): 645-651. https://doi.org/10.1016/j.placenta.2015.04.001; PMid:25904157
El Behery MM, Etewa Rasha L, El Alfy Y. (2010). Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accreta. International Journal of Gynecology & Obstetrics. 109(1): 30-33. https://doi.org/10.1016/j.ijgo.2009.11.013; PMid:20070963
Ernst LM, Linn RL, Minturn L, Miller ES. (2017). Placental pathologic associations with morbidly adherent placenta potential insights into pathogenesis. Paediatric pathology society. 20: 5. https://doi.org/10.1177/1093526617698600; PMid:28812469
Faraji A, Akbarzadeh-Jahromi M, Bahrami S, Gharamani S, Raeisi Shahraki H et al. (2022). Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum. J. Obstet. Gynaecol. 42: 900-905. https://doi.org/10.1080/01443615.2021.1955337; PMid:34558384
Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. (2014). The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG: An International Journal of Obstetrics & Gynaecology. 121(1): 62-71. https://doi.org/10.1111/1471-0528.12405; PMid:23924326 PMCid:PMC3906842
Geffen T, Gal H, Vainer I et al. (2018). Senescence and telomere homeostasis might be involved in placenta percreta - preliminary investigation. Reproductive Sciences. 25(8): 1254-1260. Epub 2017 Nov 6. https://doi.org/10.1177/1933719117737852; PMid:29108468
Gualdoni G, Gomez Castro G, Hernández R, Barbeito C, Cebral E. (2022). Comparative matrix metalloproteinase-2 and -9 expression and activity during endotheliochorial and hemochorial trophoblastic invasiveness. Tissue and Cell. 74: 101698. https://doi.org/10.1016/j.tice.2021.101698; PMid:34871824
Gu Y, Bian Y, Xu X, Wang X, Zuo C, Meng J et al. (2016). Downregulation of miR-29a/b/c in placenta accreta inhibits apoptosis of implantation site intermediate trophoblast cells by targeting MCL1. Placenta. 48: 13-19. https://doi.org/10.1016/j.placenta.2016.09.017; PMid:27871464
Gu Y, Meng J, Zuo C, Wang S, Li H, Zhao S et al. (2019). Downregulation of MicroRNA-125a in Placenta Accreta Spectrum Disorders Contributes Antiapoptosis of Implantation Site Intermediate Trophoblasts by Targeting MCL1.Reprod. Sci. 26: 1582-1589. https://doi.org/10.1177/1933719119828040; PMid:30782086
Ha M, Kim VN. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15: 509-524. https://doi.org/10.1038/nrm3838; PMid:25027649
Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell. 144(5): 646-674. https://doi.org/10.1016/j.cell.2011.02.013; PMid:21376230
Han Q, Zheng L, Liu Z, Luo J, Chen R, Yan J. (2019). Expression of β-catenin in human trophoblast and its role in placenta accreta and placenta previa. J. Int. Med. Res. 47: 206-214. https://doi.org/10.1177/0300060518799265; PMid:30465458 PMCid:PMC6384477
Hecht JL, Baergen R, Ernst LM, Katzman PJ, Jacques SM, Jauniaux E et al. (2020). Classification and reporting guidelines for the pathology diagnosis of placenta accreta spectrum (PAS) disorders: Recommendations from an expert panel. Mod. Pathol. 33: 2382-2396. https://doi.org/10.1038/s41379-020-0569-1; PMid:32415266
Heidari S, Kolahdouz-Mohammadi R, Khodaverdi S, Tajik N, Delbandi A-A. (2021). Expression levels of MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls. BMC Women's Health. 21: 422. https://doi.org/10.1186/s12905-021-01560-6; PMid:34930225 PMCid:PMC8686524
He L, Hannon GJ. (2004). MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5: 522-531. https://doi.org/10.1038/nrg1379; PMid:15211354
He Y, Ding Y, Liang B, Lin J, Kim TK, Yu H et al. (2017). A Systematic Study of Dysregulated MicroRNA in Type 2Diabetes Mellitus. Int. J. Mol. Sci. 18: 456. https://doi.org/10.3390/ijms18030456; PMid:28264477 PMCid:PMC5372489
Higgins M, Monteith C, Foley M, O'Herlihy C. (2013). Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section. European Journal of Obstetrics & Gynecology, and Reproductive Biology. 171(1): 54-56. https://doi.org/10.1016/j.ejogrb.2013.08.030; PMid:24157231
Hung TH, Shau WY, Hsieh CC, Chiu TH, Hsu JJ, Hsieh TT. (1999). Risk factors for placenta accreta. Obstetrics & Gynecology. 93(4): 545-550. https://doi.org/10.1097/00006250-199904000-00015; PMid:10214831
Illsley NP, Da Silva-Arnold SC, Zamudio S, Alvarez M, Al-Khan A. (2020). Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta). Placenta. 102: 61-66. https://doi.org/10.1016/j.placenta.2020.01.004; PMid:33218581 PMCid:PMC7680503
Jabrane-Ferrat N, Siewiera J. (2014). The up side of decidual natural killer cells: new developments in immunology of pregnancy. Immunology. 141(4): 490-497. https://doi.org/10.1111/imm.12218; PMid:24256296 PMCid:PMC3956423
Jauniaux E, Chantraine F, Silver RM, Langhoff-Roos J. (2018). FIGO consensus guidelines on placenta accreta spectrum disorders: Epidemiology. Int. J. Gynecol. Obstet. 140: 265-273. https://doi.org/10.1002/ijgo.12407; PMid:29405321
Jauniaux E, Jurkovic D. (2012). Placenta accreta: Pathogenesis of a 20th century iatrogenic uterine disease. Placenta. 33: 244-251. https://doi.org/10.1016/j.placenta.2011.11.010; PMid:22284667
Kannampuzha S, Ravichandran M, Mukherjee AG, Wanjari UR, Renu K, Vellingiri B et al. (2022). The mechanism of action of non-coding RNAs in placental disorders. Biomed. Pharmacother. 156: 113964. https://doi.org/10.1016/j.biopha.2022.113964; PMid:36411641
Kawashima A, Sekizawa A, Ventura W, Koide K, Hori K Okai T, Masashi Y et al. (2014). Increased levels of cell-free human placental lactogen mRNA at 28-32 gestational weeks in plasma of pregnant women with placenta previa and invasive placenta. Reprod. Sci. 21: 215-220. https://doi.org/10.1177/1933719113492209; PMid:23744883 PMCid:PMC3879989
Knight M, Nair M, Tuffnell D et al. (2017). Saving Lives, Improving Mothers' Care - Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-15, National Perinatal Epidemiology Unit, University of Oxford. Oxford.
Kocarslan S, Incebıyık A, Guldur ME, Ekinci T, Ozardali HI. (2015). What is the role of matrix metalloproteinase-2 in placenta percreta? Journal of Obstetrics and Gynaecology Research. 41(7): 1018-1022. https://doi.org/10.1111/jog.12667; PMid:25656855
Laban M, Ibrahim EA-S, Elsafty MSE, Hassanin AS. (2014). Placenta accreta is associated with decreased decidual natural killer (dNK) cells population: a comparative pilot study. European Journal of Obstetrics & and Reproductive Biology. 181: 284-288. https://doi.org/10.1016/j.ejogrb.2014.08.015; PMid:25195203
Laursen LS, Kjaer-Sorensen K, Andersen MH, Oxvig C. (2007). Regulation of insulin-like growth factor (IGF) bioactivity by sequential proteolytic cleavage of IGF binding protein- and -5. Molecular Endocrinology. 21(5): 1246-1257. https://doi.org/10.1210/me.2006-0522; PMid:17312271
Lawrence JB, Oxvig C, Overgaard MT et al. (1999). The insulinlike growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancyassociated plasma protein-A. Proceedings of the National Academy of Sciences of the United States of America. 96(6): 3149-3153. https://doi.org/10.1073/pnas.96.6.3149; PMid:10077652 PMCid:PMC15910
Li J, Zhang N, Zhang Y, Hu X, Gao G, Ye Y et al. (2019). Human placental lactogen mRNA in maternal plasma play a role in prenatal diagnosis of abnormally invasive placenta: Yes or no? Gynecol. Endocrinol. 35: 631-634. https://doi.org/10.1080/09513590.2019.1576607; PMid:30784325
Li R, Wang W, Qiu X, He M, Tang X, Zhong M. (2023). Periostin promotes extensive neovascularization in placenta accreta spectrum disorders via Notch signaling. J. Matern.-Fetal Neonatal Med. 36: 2264447. https://doi.org/10.1080/14767058.2023.2264447; PMid:37806775
Lin T-M, Halbert SP, Kiefer D, Spellacy WN, Gall S. (1974). Characterization of four human pregnancy-associated plasma proteins. American Journal of Obstetrics & Gynecology. 118(2): 223-236. https://doi.org/10.1016/0002-9378(74)90553-5; PMid:4129188
Liu DF, Dickerman LH, Redline RW. (1999). Pathologic findings in pregnancies with unexplained increases in midtrimester maternal serum human chorionic gonadotropin levels. American Journal of Clinical Pathology. 111(2): 209-215. https://doi.org/10.1093/ajcp/111.2.209; PMid:9930142
Liu M, Su C, Zhu L, Dong F, Shu H, Zhang H et al. (2023). Highly expressed FYN promotes the progression of placenta accreta by activating STAT3, p38, and JNK signaling pathways. Acta Histochem. 125: 151991. https://doi.org/10.1016/j.acthis.2022.151991; PMid:36563468
Liu X, Wang Y. Wu Y, Zeng J, Yuan X, Tong C, Qi H. (2021). What we know about placenta accreta spectrum (PAS). Eur. J. Obstet. Gynecol. Reprod. Biol. 259: 81-89. https://doi.org/10.1016/j.ejogrb.2021.02.001; PMid:33601317
Long Y, Chen Y, Fu XQ, Yang F, Chen ZW, Mo GL et al. (2019). Research on the expression of MRNA-518b in the pathogenesis of placenta accreta. Eur. Rev. Med. Pharmacol. Sci. 23: 23-28.
Long Y, Jiang Y, Zeng J, Dang Y, Chen Y, Lin J et al. (2020). The expression and biological function of chemokine CXCL12 and receptor CXCR4/CXCR7 in placenta accreta spectrum disorders. J. Cell. Mol. Med. 24: 3167-3182. https://doi.org/10.1111/jcmm.14990; PMid:31991051 PMCid:PMC7077540
Lo YM, Corbetta N, Chamberlain PF et al. (1997). Presence of fetal DNA in maternal plasma and serum. The Lancet. 350(9076): 485-487. https://doi.org/10.1016/S0140-6736(97)02174-0; PMid:9274585
Lumbanraja S, Yaznil MR, Siahaan AM, Berry Eka Parda B. (2022). Soluble FMS-Like Tyrosine Kinase-1: Role in placenta accreta spectrum disorder. F1000Research. 10: 618. https://doi.org/10.12688/f1000research.54719.4; PMCid:PMC9478500
Lyell DJ, Faucett AM, Baer RJ, Blumenfeld YJ, Druzin ML, El-Sayed YY et al. (2015, Aug). Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. J Perinatol. 35(8): 570-574. Epub 2015 Apr 30. https://doi.org/10.1038/jp.2015.40; PMid:25927270
Markfeld Erol F, Hausler JA, Medl M, Juhasz-Boess I, Kunze M. (2024). Placenta Accreta Spectrum (PAS): Diagnosis, Clinical Presentation, Therapeutic Approaches, and Clinical Outcomes. Medicina. 60: 1180. https://doi.org/10.3390/medicina60071180; PMid:39064609 PMCid:PMC11278763
Maron JL, Bianchi DW. (2007). Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. American Journal of Medical Genetics Part C, Seminars in Medical Genetics. 145C(1): 5-17. https://doi.org/10.1002/ajmg.c.30115; PMid:17299735
Marshall NE, Fu R, Guise JM. (2011). Impact of multiple cesarean deliveries on maternal morbidity: A systematic review. Am. J.Obstet. Gynecol. 205: 262.e1-262.e8. https://doi.org/10.1016/j.ajog.2011.06.035; PMid:22071057
Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L et al. (2023). Long non-coding RNAs: Definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol. 24: 430-447. https://doi.org/10.1038/s41580-022-00566-8; PMid:36596869 PMCid:PMC10213152
Mizejewski GJ. (2001). Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Experimental Biology and Medicine. 226(5): 377-408. https://doi.org/10.1177/153537020122600503; PMid:11393167
Mizejewski GJ. (2007). Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Experimental Biology and Medicine. 232(8): 993-1004. https://doi.org/10.3181/0612-MR-291; PMid:17720945
Monteiro LJ, Penailillo R, Sánchez M, Acuna-Gallardo S, Monckeberg M, Ong J et al. (2021). The Role of Long Non-Coding RNAs in Trophoblast Regulation in Preeclampsia and Intrauterine Growth Restriction. Genes. 12: 970. https://doi.org/10.3390/genes12070970; PMid:34201957 PMCid:PMC8305149
Murrieta-Coxca JM, Barth E, Fuentes-Zacarias P, Gutiérrez-Samudio RN, Groten T, Gellhaus A et al. (2023). Identification of altered miRNAs and their targets in placenta accreta. Front. Endocrinol. 14: 1021640. https://doi.org/10.3389/fendo.2023.1021640; PMid:36936174 PMCid:PMC10022468
NCBI. (2018, Feb). Entrez gene: PAPPA pregnancy-associated plasma protein A, pappalysin 1. URL: https://www.ncbi.nlm.nih.govgene?Db=gene&Cmd=ShowDetailView&TermToSearch=5069.
Ng EK, Tsui NB, Lau TK et al. (2003). mRNA of placental origin is readily detectable in maternal plasma. Proceedings of the National Academy of Sciences of the United States of America. 100(8): 4748-4753. https://doi.org/10.1073/pnas.0637450100; PMid:12644709 PMCid:PMC153627
O'Brien JM, Barton JR, Donaldson ES. (1996). The management of placenta percreta: conservative and operative strategies. American Journal of Obstetrics & Gynecology. 175(6): 1632-1638. https://doi.org/10.1016/S0002-9378(96)70117-5; PMid:8987952
Oztas E, Ozler S, Caglar AT, Yucel A. (2016). Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy. Kaohsiung J. Med. Sci. 32: 579-585. https://doi.org/10.1016/j.kjms.2016.08.011; PMid:27847101
Penzhoyan GA, Makukhina TB. (2019). Significance of the routin first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. J. Perinat. Med. 48: 21-26. https://doi.org/10.1515/jpm-2019-0261; PMid:31730533
Pinas Carrillo A, Chandraharan E. (2019). Placenta accreta spectrum: Risk factors, diagnosis and management with special reference to the Triple P procedure. Women's Health. 15: 1745506519878081. https://doi.org/10.1177/1745506519878081; PMid:31578123 PMCid:PMC6777059
Romeo V, Verde F, Sarno L, Migliorini S, Petretta M, Mainenti PP et al. (2021). Prediction of placenta accreta spectrum in patients with placenta previa using clinical risk factors, ultrasound and magnetic resonance imaging findings. La Radiol. Medica. 126: 1216-1225. https://doi.org/10.1007/s11547-021-01348-6; PMid:34156592
Samuel A, Bonanno C, Oliphant A, Batey A, Wright JD. (2013). Fraction of cell-free fetal DNA in the maternal serum as a predictor of abnormal placental invasion-a pilot study. Prenatal Diagnosis. 33(11): 1050-1053. https://doi.org/10.1002/pd.4195; PMid:23836321
Schwickert A, Chantraine F, Ehrlich L, Henrich W, Muallem MZ, Nonnenmacher A et al. (2021). Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: A Multicenter Case-Control Study. Reprod.Sci. 28: 361-370. https://doi.org/10.1007/s43032-020-00319-y; PMid:33025531 PMCid:PMC7808970
Sekizawa A, Jimbo M, Saito H et al. (2002). Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clinical Chemistry. 48(2): 353-354. https://doi.org/10.1093/clinchem/48.2.353; PMid:11805017
Silahtaroglu AN, Tumer Z, Kristensen T, Sottrup-Jensen L, Tommerup N. (1993). Assignment of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in situ hybridization to mitotic and meiotic chromosomes. Cytogenetics and Cell Genetics. 62(4): 214-216. https://doi.org/10.1159/000133479; PMid:7679961
Silver RM, Barbour KD. (2015). Placenta accreta spectrum: accreta, increta, and percreta. Obstetrics and Gynecology Clinics of North America. 42(2): 381-402. https://doi.org/10.1016/j.ogc.2015.01.014; PMid:26002174
Shainker SA, Silver RM, Modest AM, Hacker MR, Hecht JL, Salahuddin S et al. (2020). Placenta accreta spectrum: Biomarker discovery using plasma proteomics. Am. J. Obstet. Gynecol. 223: 433.e1-433.e14. https://doi.org/10.1016/j.ajog.2020.03.019; PMid:32199927
Shih JC, Lin HH, Hsiao AC, Su YT, Tsai S, Chien CL, Kung HN. (2019). Unveiling the role of microRNA-7 in linkingTGF-β-Smad-mediated epithelial-mesenchymal transition with negative regulation of trophoblast invasion. FASEB J. 33: 6281-6295. https://doi.org/10.1096/fj.201801898RR; PMid:30789794
Shi Q, Lei Z, Rao CV, Lin J. (1993). Novel role of human chorionic gonadotropin in differentiation of human cytotro- phoblasts. Endocrinology. 132(3): 1387-1395. https://doi.org/10.1210/endo.132.3.7679981; PMid:7679981
Tantbirojn P, Crum CP, Parast MM. (2008). Pathophysiology of Placenta Creta: The Role of Decidua and Extravillous Trophoblast. Placenta. 29: 639-645. https://doi.org/10.1016/j.placenta.2008.04.008; PMid:18514815
Thompson O, Ogbah C, Nnochiri A, Sumithran E, Spencer K. (2015). First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. BJOG: An International Journal of Obstetrics and Gynaecology. 122(10): 1370-1376. https://doi.org/10.1111/1471-0528.13298; PMid:25639820
Tul N, Tul N, Pušenjak S, Osredkar J, Spencer K, Novak-Antolič Ž. (2003). Predicting complications of pregnancy with first-trimester maternal serum free-βhCG, PAPP-A and inhibin-A. Prenatal Diagnosis. 23(12): 990-996. https://doi.org/10.1002/pd.735; PMid:14663836
Waller DK, Lustig LS, Smith AH, Hook EB. (1993). Alphafetoprotein: a biomarker for pregnancy outcome. Epidemiology. 4(5): 471-476. https://doi.org/10.1097/00001648-199309000-00014; PMid:7691189
Wang R, Liu W, Zhao J, Liu L, Li S, Duan Y, Huo Y. (2023). Overexpressed LAMC2 promotes trophoblast over-invasion through the PI3K/Akt/MMP2/9 pathway in placenta accreta spectrum. J. Obstet. Gynaecol. Res. 49: 548-559. https://doi.org/10.1111/jog.15493; PMid:36412218
Wang R, Zhao J, Liu C, Li S, Liu W, Cao Q. (2023). Decreased AGGF1 facilitates the progression of placenta accreta spectrum via mediating the P53 signaling pathway under the regulation of miR-1296-5p. Reprod. Biol. 23: 100735. https://doi.org/10.1016/j.repbio.2023.100735; PMid:36753931
Xie L, Sadovsky Y. (2016). The function of miR-519d in cell migration, invasion, and proliferation suggests a role in early placentation. Placenta. 48: 34-37. https://doi.org/10.1016/j.placenta.2016.10.004; PMid:27871470 PMCid:PMC5130096
Ye J, Zhang J, Mikolajczyk R, Torloni MR, Gulmezoglu AM, Betran AP. (2016). Association between rates of caesarean section and maternal and neonatal mortality in the 21st century: A worldwide population-based ecological study with longitudinal data. BJOG Int. J. Obstet. Gynaecol. 123: 745-753. https://doi.org/10.1111/1471-0528.13592; PMid:26331389 PMCid:PMC5014131
Zhang F, Gu M, Chen P; Wan S, Zhou Q, Lu Y, Li L. (2022). Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio. Placenta. 124: 48-54. https://doi.org/10.1016/j.placenta.2022.05.009; PMid:35635854
Zhang T, Wang S. (2022). Potential Serum Biomarkers in Prenatal Diagnosis of Placenta Accreta Spectrum. Front. Med. 9: 860186. https://doi.org/10.3389/fmed.2022.860186; PMid:35712096 PMCid:PMC9196238
Zheng W, Zhang H, Ma J, Dou R, Zhao X et al. (2022). Validation of a scoring system for prediction of obstetric complications in placenta accreta spectrum disorders. J. Matern.-Fetal Neonatal Med. 35: 4149-4155. https://doi.org/10.1080/14767058.2020.1847077; PMid:33685330
Zhou J, Li J, Yan P, Ye YH, Peng W, Wang S, Wang XT. (2014). Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta. 35: 691-695. https://doi.org/10.1016/j.placenta.2014.07.007; PMid:25063251
Zhu JY, Pang ZJ, Yu YH. (2012). Regulation of trophoblast invasion: the role of matrix metalloproteinases. Reviews in Obstetrics & Gynecology. 5(3-4): e137-e143.
Zelop C, Nadel A, Frigoletto FD Jr, Pauker S, MacMillan M, Benacerraf BR. (1992). Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.Obstetrics and Gynecology. 80(4): 693-694.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
